fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Clotrimazole

Form:

7 of 7 products shown

6 general benefit · 1 not a benefit

Clotrimaderm · DIN 00812382 · 10 mg/g · Cr

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Clotrimaderm · DIN 00812382 Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01 Health Canada: Marketed since 2022-07-05 · brand CLOTRIMADERM TOPICAL · ATC D01AC01 CLOTRIMAZOLE · form Cream · route Topical · ingredients CLOTRIMAZOLE 1 % · company Taro pharmaceuticals inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Clotrimaderm: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2233). What the ministry pays, not the patient.

Ministry pays: $0.2233 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00812382)

Source record
DIN 00812382: Clotrimaderm Raw flags: sec3=Y Item: 840408012; group id 818; item number 1997; lccId None; manufacturer id TAR Source form: Cr; strength: 10mg/g Recorded listing: General benefit Source prices (unrounded): $0.2233; ministry $0.2233 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00812382 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11893
Interchangeable products
Canesten 1% Topical Cream · DIN 02150867 · not recorded
Shortage status: discontinued (February 20, 2026, reported by TARO PHARMACEUTICALS INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00812382
Shortage record checked October 6, 2026

Canesten 6 Cream · DIN 02150891 · 10 mg/g · Vag Cr-App

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Canesten 6 Cream · DIN 02150891 Manufacturer: Bayer Inc., Consumer Care Division; listing date 1996-10-01 Health Canada: Marketed since 2018-11-09 · brand CANESTEN 6 DAY INTERNAL CREAM · ATC G01AF02 CLOTRIMAZOLE · form Cream · route Vaginal · ingredients CLOTRIMAZOLE 1 %/W/W · company Bayer inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $0.1812 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02150891)

Source record
DIN 02150891: Canesten 6 Cream Raw flags: sec3=Y Item: 840408017; group id 818; item number 1999; lccId None; manufacturer id BAY Source form: Vag Cr-App; strength: 10mg/g Recorded listing: General benefit Source prices (unrounded): $0.2212; ministry $0.1812 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02150891 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19483
Interchangeable products
Clotrimaderm Vaginal Cream · DIN 00812366 · $0.1812
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02150891
Shortage record checked October 6, 2026

Clotrimaderm Vaginal Cream · DIN 00812366 · 10 mg/g · Vag Cr-App

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Clotrimaderm Vaginal Cream · DIN 00812366 Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01 Health Canada: Marketed since 2020-02-21 · brand CLOTRIMADERM VAGINAL 6 · ATC G01AF02 CLOTRIMAZOLE · form Cream · route Vaginal · ingredients CLOTRIMAZOLE 1 %/W/W · company Taro pharmaceuticals inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Clotrimaderm Vaginal Cream: Formulary list price $0.18 per unit (the source does not state the unit; exact figure $0.1812). What the ministry pays, not the patient.

Ministry pays: $0.1812 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00812366)

Source record
DIN 00812366: Clotrimaderm Vaginal Cream Raw flags: sec3=Y Item: 840408017; group id 818; item number 1999; lccId None; manufacturer id TAR Source form: Vag Cr-App; strength: 10mg/g Recorded listing: General benefit Source prices (unrounded): $0.1812; ministry $0.1812 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00812366 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9926
Interchangeable products
Canesten 6 Cream · DIN 02150891 · $0.1812
Shortage status: active shortage (reported June 17, 2026, estimated to end November 27, 2026, last updated August 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00812366
Shortage record checked October 6, 2026

Canesten 3 Cream · DIN 02150905 · 20 mg/g · Vag Cr-App

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Canesten 3 Cream · DIN 02150905 Manufacturer: Bayer Inc., Consumer Care Division; listing date 1996-10-01 Health Canada: Marketed since 2018-11-09 · brand CANESTEN 3 DAY INTERNAL CREAM · ATC G01AF02 CLOTRIMAZOLE · form Cream · route Vaginal · ingredients CLOTRIMAZOLE 2 %/W/W · company Bayer inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $0.3624 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02150905)

Source record
DIN 02150905: Canesten 3 Cream Raw flags: sec3=Y Item: 840408027; group id 818; item number 2000; lccId None; manufacturer id BAY Source form: Vag Cr-App; strength: 20mg/g Recorded listing: General benefit Source prices (unrounded): $0.4424; ministry $0.3624 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02150905 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19484
Interchangeable products
Clotrimaderm Vaginal Cream · DIN 00812374 · $0.3624
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02150905
Shortage record checked October 6, 2026

Clotrimaderm Vaginal Cream · DIN 00812374 · 20 mg/g · Vag Cr-App

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Clotrimaderm Vaginal Cream · DIN 00812374 Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01 Health Canada: Marketed since 2020-02-21 · brand CLOTRIMADERM VAGINAL 3 · ATC G01AF02 CLOTRIMAZOLE · form Cream · route Vaginal · ingredients CLOTRIMAZOLE 2 %/W/W · company Taro pharmaceuticals inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Clotrimaderm Vaginal Cream: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3624). What the ministry pays, not the patient.

Ministry pays: $0.3624 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00812374)

Source record
DIN 00812374: Clotrimaderm Vaginal Cream Raw flags: sec3=Y Item: 840408027; group id 818; item number 2000; lccId None; manufacturer id TAR Source form: Vag Cr-App; strength: 20mg/g Recorded listing: General benefit Source prices (unrounded): $0.3624; ministry $0.3624 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00812374 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9927
Interchangeable products
Canesten 3 Cream · DIN 02150905 · $0.3624
Shortage status: resolved shortage (ended October 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00812374
Shortage record checked October 6, 2026

Canesten 1 Comfortab Combi-Pak · DIN 02264102 · 500 mg & 1% · tablet & Cr

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Canesten 1 Comfortab Combi-Pak · DIN 02264102 Manufacturer: Bayer Inc., Consumer Care Division; listing date 2007-01-02 Health Canada: Marketed since 2023-02-21 · brand CANESTEN COMBI 1 DAY · ATC G01AF02 CLOTRIMAZOLE · form Cream, Vaginal tablet, Kit · route Vaginal, Topical · ingredients CLOTRIMAZOLE 1 %/W/W, CLOTRIMAZOLE 500 MG/VTAB · company Bayer inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Canesten 1 Comfortab Combi-Pak: Formulary list price $12.08 per unit (the source does not state the unit; exact figure $12.0800). What the ministry pays, not the patient.

Ministry pays: $12.0800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02264102)

Source record
DIN 02264102: Canesten 1 Comfortab Combi-Pak Raw flags: sec3=Y Item: 840408035; group id 818; item number 1998; lccId None; manufacturer id BAY Source form: Tab & Cr; strength: 500mg & 1% Recorded listing: General benefit Source prices (unrounded): $12.0800; ministry $12.0800 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02264102 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74952
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02264102
Shortage record checked October 6, 2026

Canesten 1% Topical Cream · DIN 02150867 · 10 mg/g · Cr

Listed, not a benefitMarketed · checked October 5, 2026
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Canesten 1% Topical Cream · DIN 02150867 Manufacturer: Bayer Inc., Consumer Care Division; listing date 1996-10-01 Health Canada: Marketed since 1995-12-31 · brand CANESTEN 1% TOPICAL CREAM · ATC D01AC01 CLOTRIMAZOLE · form Cream · route Topical · ingredients CLOTRIMAZOLE 1 %/% · company Bayer inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Canesten 1% Topical Cream: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02150867)

Source record
DIN 02150867: Canesten 1% Topical Cream Raw flags: notABenefit=Y, sec3=Y Item: 840408012; group id 818; item number 1997; lccId None; manufacturer id BAY Source form: Cr; strength: 10mg/g Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02150867 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19487
Interchangeable products
Clotrimaderm · DIN 00812382 · $0.2233
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02150867
Shortage record checked October 6, 2026

Other products in the same Health Canada class (D01A, D01AC, G01A): coverage varies; not interchangeable

  • Ketoconazole (Nizoral): general benefit, not a benefit
  • Miconazole nitrate (Micatin): general benefit
  • Nystatin (Mycostatin): general benefit, not a benefit
  • Terbinafine (Lamisil): general benefit
  • Terconazole (Terazol 7): general benefit, not a benefit
  • Ciclopirox (Penlac): not a benefit

Clotrimazole & betamethasone dipropionate

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

Lotriderm Cream · DIN 00611174 · 1% w/w & 0.05% w/w · Top Cr

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Savings card: RxHelp ONE lists LOTRIDERM CREAM (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Lotriderm Cream · DIN 00611174 Manufacturer: Merck Canada Inc.; listing date 2020-06-30 Health Canada: Marketed since 2022-03-10 · brand LOTRIDERM · ATC D01AC20 IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS, D01AC20 IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %, CLOTRIMAZOLE 1 % · company Organon canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Lotriderm Cream: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00611174)

Source record
DIN 00611174: Lotriderm Cream Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840408056; group id 819; item number 2001; lccId None; manufacturer id MEK Source form: Top Cr; strength: 1% w/w & 0.05% w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00611174 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10748
Interchangeable products
TaroClotrimazole/BetamethasoneDipropiona · DIN 02496410 · not recorded
Shortage status: resolved shortage (ended April 2, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00611174
Shortage record checked October 6, 2026

TaroClotrimazole/BetamethasoneDipropiona · DIN 02496410 · 1% w/w & 0.05% w/w · Top Cr

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
TaroClotrimazole/BetamethasoneDipropiona · DIN 02496410 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2020-06-30 Health Canada: Marketed since 2020-04-06 · brand TARO-CLOTRIMAZOLE/BETAMETHASONE DIPROPIONATE · ATC D01AC20 IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS · form Cream · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %/W/W, CLOTRIMAZOLE 1 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02496410)

Source record
DIN 02496410: TaroClotrimazole/BetamethasoneDipropiona Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840408056; group id 819; item number 2001; lccId None; manufacturer id TAR Source form: Top Cr; strength: 1% w/w & 0.05% w/w Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.0832; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02496410 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98629
Interchangeable products
Lotriderm Cream · DIN 00611174 · not recorded
Shortage status: resolved shortage (ended February 4, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02496410
Shortage record checked October 6, 2026

Other products in the same Health Canada class (D01A, D01AC, G01A): coverage varies; not interchangeable

  • Ketoconazole (Nizoral): general benefit, not a benefit
  • Miconazole nitrate (Micatin): general benefit
  • Nystatin (Mycostatin): general benefit, not a benefit
  • Terbinafine (Lamisil): general benefit
  • Terconazole (Terazol 7): general benefit, not a benefit
  • Ciclopirox (Penlac): not a benefit
Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered

Matched class: 84:04:08 Fungicides

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL Some products covered without a code (check the product listing): KETOCONAZOLE, NYSTATIN, TERCONAZOLE 84:04:08 Fungicides

KETOCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Cr

MICONAZOLE NITRATE

· 1 products · General benefit · strengths: 2% · Cr

NYSTATIN

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 100000U/g, 25000U/g · Cr, Oint, Vag Cr

TERBINAFINE HCL

· 1 products · General benefit · strengths: 1% · Cr

TERCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.4% · Vag Cr

CICLOPIROX

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8% W/W · Top Sol

FLUCONAZOLE

· 9 products · Limited Use, codes 235 · strengths: 150mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:08
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Clotrimaderm Vaginal 6 (clotrimazole) is indicated for the 6-day treatment of vaginal candidiasis. Clotrimaderm Vaginal 3 (clotrimazole) is indicated for the 3-day treatment of vaginal candidiasis. 1.1 Pediatrics Pediatrics (>12 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of Clotrimazole in pediatric patients (>12 years of age) has been established. Therefore, Health Canada has authorized an indication for pediatric (>12 years of age) use. https://pdf.hres.ca/dpd_pm/00081078.PDF PM date: July 16, 2025 Source product: CLOTRIMADERM VAGINAL 6; DIN 00812366; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS LOTRIDERM® Cream (betamethasone dipropionate and clotrimazole) is indicated for:  the topical treatment of the following fungal dermal infections complicated by inflammatory pruritus: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis. 1.1 Pediatrics Pediatrics: Based on the available data, the safety and effectiveness in children below the age of 12 have not been established with LOTRIDERM® Cream. 1.2 Geriatrics Geriatrics: There is insufficient data to suggest that use in the geriatric population is associated with differences in safety or effectiveness. https://pdf.hres.ca/dpd_pm/00060782.PDF PM date: April 20, 2021 Source product: LOTRIDERM; DIN 00611174; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Clotrimaderm · DIN 00812382 Shortage status: discontinued (2026-02-20, reported by TARO PHARMACEUTICALS INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00812382

Check this DIN again

Clotrimaderm Vaginal Cream · DIN 00812366 Shortage status: active shortage (reported 2026-06-17, estimated to end 2026-11-27, last updated 2026-08-17); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00812366

Check this DIN again

Other review policies

For Canesten 1% Topical Cream, Lotriderm Cream, TaroClotrimazole/BetamethasoneDipropiona: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026